ResMed Inc. (NASDAQ: RMD) leadership has seen recent movement in equity holdings following a period of varied financial reporting. Michael J. Farrell, serving as both Chairman and CEO, sold 4,991 shares of ResMed common stock on May 7, 2026. The total value realized from this transaction was $1,037,232.
The sale was preceded by the acquisition of the same number of shares. Mr. Farrell exercised options to acquire 4,991 shares at a strike price of $146.34 per share, representing a total cost of $730,382. These specific options had been exercisable since November 11, 2020, and were scheduled to expire on November 21, 2026. The shares sold in the May transaction were executed at various prices between $206.45 and $210.47, resulting in a weighted average sale price of $207.8206 per share.
Following these recent transactions, Mr. Farrell maintains a direct holding of 466,223 shares of ResMed common stock. Furthermore, he holds an indirect interest of 2,090 shares through the Lisette and Michael Farrell Family Trust.
Market Context and Financial Performance
The insider activity occurs against a backdrop of recent fiscal third-quarter earnings for 2026, which presented a complicated financial picture for the company. ResMed reported earnings per share of $2.86, which surpassed the anticipated figure of $2.81 by 1.78%. However, revenue figures fell slightly short of expectations; the company reported $1.43 billion in revenue against a forecast of $1.42 billion, reflecting a miss of 1.41%.
Analyst perspectives on ResMed remain divided. RBC Capital has maintained an Outperform rating and increased its price target from $314 to $321, noting that the company's double-digit growth in both earnings and revenue exceeded consensus estimates. In contrast, Wolfe Research has lowered its price target for the stock from $230 to $180 while maintaining an Underperform rating. Wolfe Research is applying a 15 times multiple to projected next-twelve-month earnings per share of approximately $11.90 and anticipates ResMed will act as an organic grower at a rate of 6% to 7% moving forward.
Key Insights
- Executive Liquidity via Scheduled Plans: The use of a Rule 10b5-1 plan, adopted in late 2024, demonstrates the structured nature of executive equity management.
- Divergent Valuation Metrics: While some analysts see room for growth, others project more modest organic expansion, impacting investor sentiment within the healthcare technology sector.
- Mixed Earnings Signals: The discrepancy between exceeding EPS targets while missing revenue targets highlights specific operational nuances in ResMed's recent fiscal performance.
Risk Factors and Uncertainties
- Analyst Disparity: The significant gap between RBC Capital's $321 target and Wolfe Research's $180 target creates uncertainty regarding the stock's intrinsic value and future trajectory in the medical device market.
- Growth Projections: Uncertainty remains regarding whether the company can sustain the double-digit growth noted by some or if it will settle into the 6% to 7% organic growth range projected by others.
- Revenue Volatility: The recent revenue miss, despite an earnings beat, suggests potential volatility in top-line performance that could impact broader healthcare sector stability.